HK Stock Market Move | LEADS BIOLABS-B (09887) rises over 6% again, and Wellyx's Phase II study for the first-line treatment of hepatocellular carcinoma enters the expansion stage.

LEADS BIOLABS-B (09887) has risen more than 6%, with a cumulative increase of over 36% this month. As of the time of writing, it is up 6.07%, priced at HKD 73.35, with a transaction volume of HKD 131 million. In news, Weili Zhibo recently announced that the companys independently developed PD-L1/4-1BB bispecific antibody, Velixin (LBL-024), has successfully progressed into the expansion phase after the safety induction period evaluation was completed by experts during the Phase II clinical study for first-line treatment of hepatocellular carcinoma. Public information shows that Velixin has demonstrated strong efficacy signals and breakthrough therapeutic potential across multiple tumor types, including lung neuroendocrine carcinoma, non-small cell lung cancer, small cell lung cancer, and cholangiocarcinoma. Utilizing the conditional activation design of the X-body platform, it has confirmed good safety in nearly 800 patients. The recent verification in liver cancer further solidifies Velixin as a safe foundational therapy in IO 2.0 for various tumors.